POTENTIAL ROLE OF Jasonia montanta AND Jasonia candicans AGAINST ALZ- HEIMER'S DISEASE: ASSESSMENT OF OXIDATIVE STRESS AND GENE EX- PRESSION CHANGES IN AD-INDUCED RATS

Authors

  • SABAH A. A. LINJAWI Biology Department, College of Science, King AbdulAziz University, Saudi Arabia
  • EKRAM S. AHMED Cell Biology Department, National Research Centre, 12622 Dokki, Giza, Egypt
  • W. K. B. KHALIL Cell Biology Department, National Research Centre, 12622 Dokki, Giza, Egypt
  • HODA F. BOOLES Cell Biology Department, National Research Centre, 12622 Dokki, Giza, Egypt

Abstract

Oxidative stress-induced damage was shown to be one of the important mechanisms to indicate that aluminum has an association with the etiology of Alzheimer's disease (Kumar et al., 2009). Increased generation of reactive oxygen species (ROS) and lipid peroxidation has been found to be involved in the pathogenesis of many diseases of known and unknown etiology and in the toxic actions of many compounds (Andallu and Varadacharyulu, 2003). Aluminium is a nonredox active metal which is capable of increasing the cellular oxidative milieu by potentiating the pro-oxidant properties of transition metals such as iron and copper (Bjertness et al., 1996). An unusual aspect of the biochemistry of this non-redox active metal is its pro-oxidant activity, which might be explained by the formation of an Al superoxide semi-reduced biological macromolecules, including lipids, proteins, nucleic acids, and carbohydrates. The resulting stress increases neuronal death, which contributes to the neuropathology associated with several diseases (Baydas et al., 2003).
Gene expression changes in the forebrain occur during normal and pathological aging. Altered gene expression is thought to contribute to the balance between normal aging and age-related memory disorders, including Alzheimer's dis- ease (AD) (Berchtold et al., 2008). Synap- tic dysfunction in AD is apparent before synapse and neuron loss and caused likely by accumulation of β-amyloid (Aβ) pep- tides (Selkoe, 2002). The cellular mecha- nisms underlying synaptic and memory dysfunction caused by altered activity- dependent gene transcription in AD are radical ion (AlO2) (Exley, 2005). It has largely unknown. Understanding the mobeen shown that chronic aluminium exposure is involved in the impairment of mitochondrial electron transport chain (ETC) and increased production of ROS (Kumar et al., 2008). The formation of excessive ROS and reactive nitrogen species (RNS) can lead to oxidative injury. Reactive oxygen species (ROS) interact with all lecular pathways regulating gene expression profiles in memory disorders may allow the identification of new signaling pathways for drug discovery (Altar et al., 2009). Several PCR techniques are used to determine the changes in the gene expression, in which the most aqurat one is Realtime-PCR (RT-PCR). It is became the most popular method of quantitating steady-state mRNA levels (Bustin, 2000). It is most often used for two reasons: either as a primary investigative tool to determine gene expression or as a secondary tool to validate the results of DNA microarrays. Because of the precision and sensitivity of real-time RT-PCR, even subtle changes in gene expression can be detected. Thus real-time PCR can be used to assess RNA levels with great sensitivity and precision.
There are several genes play main role in occurrence the AD diseases. The generation of amyloid β-peptide (Aβ) is widely held to play an early and critical role in the pathogenesis of Alzheimer’s disease (Hardy and Selkoe, 2002). Aβ is generated from the large precursor protein amyloid precursor protein (APP) by the sequential action of two proteases, β and γ-secretase. β-secretase has been identified as β-site APP-cleaving enzyme 1 (BACE1) which, together with its homolog BACE2, forms a novel subfamily of transmembrane aspartic proteases within the pepsin family (Vassar and Citron, 2000).
The formation of Alzheimer’s Aβ peptide is initiated when the amyloid precursor protein (APP) is cleaved by the enzyme β-secretase (BACE1); inhibition of this cleavage has been proposed as a means of treating Alzheimer’s disease.
Cyclooxygenase (COX-2) is continuously expressed within a distinct population of neurons in the brain (Breder et al., 1995), which is a common attribute in enzymes involved in physiological functions of the central nervous system such as memory, sensory integration, and autonomic regulation (Kaufmann et al., 1997). On the other hand, in various neuropathological conditions accompanied by inflammatory reaction, such as stroke (Tomimoto et al., 2000) and amyotrophic lateral sclerosis (ALS) (Yasojima et al., 2001), COX-2 up-regulation is thought to mediate neuronal damage presumably by producing excessive amounts of harmful prostanoids and free radicals. In AD brains, it has been reported that the expression of COX-2 mRNA and protein was elevated (Yasojima et al., 1999). However, it is not yet completely delineated how and in what type of cells COX-2 is increased in the AD brain.
Aluminum-induced depletion of antioxidants such as glutathione (GSH), glutathione peroxidase (GSH-Px), glutathione S-transferase (GST) and catalase (CAT) (Mahieu et al., 2005). Antioxidants thus play key roles in the protection against damage caused by reactive oxygen species (Baynes, 1991). Many plant extracts and plant products have been shown to have significant antioxidant activity (Anjali and Manoj, 1995), which may be an important property of medicinal plants associated with the treatment of several diseases including neurodegenerative diseases. Thus, herbal plants are considered useful means to prevent and/or ameliorate certain disorders, such as Alzheimer's disease. Among these herbal resources, the plant Jasonia montana and Jasonia candicans occur in the Mediterranean and surrounding areas (Merxmuller et al., 1977), including the Sinai Peninsula (Tackholm, 1974). The herb has a strong aromatic odor and is used in traditional medicine for diarrhea, stomach ache, and chest diseases (Tackholm, 1969). A literature survey indicated that some mono- and ses- quiterpenes (Ahmed and Jakupovic, 1990; Ahmed, 1991), flavonoids (Ahmed et al., 1989) and essential oils (Hammerschmidt et al., 1993) have been reported from the plant.
Rivastigmine is a carbamate derivative pseudo-irreversible cholinesterase inhibitor which can both inhibit acetylcho-linesterase (AChE) and butyrylcholi-nesterase (BuChE1). This drug is licensed for use in the UK for the symptomatic treatment of mild-to-moderately severe AD due to its inhibitory action on AchE activity (Foye et al., 1995). Rivastigmine has been reported to protect mice against cognitive impairment caused by oxygen deficit, improve learning in rats, and antagonize scopolamine induced impairment of cognitive function in rats (Desai and Grossberg, 2001; Howes et al., 2003). It has been demonstrated that Rivastigmine supplementation increased the concentration of acetylcholine and inhibited acetylcholine esterase activity (Liang and Tang, 2004).
The present study was designed to investigate the potential role of J. montanta and J. candicans total extracts against AlCl3-induced oxidative stress and gene expression alteration of AD-related enzymes characterizing Alzheimer's disease in male rats.

References

Ahmed, A. A. (1991). Two geraniol derivatives from Jasonia Montana. Pharmazie, 46: 362-63.

Ahmed, A. A. and S. Jakupovic (1990). Sesqui and monoterpenes from Jasonia montana. J. Phytochemistry, 29: 3656-3661.

Ahmed, A. A., A. A. Ali and T. J. Mabry (1989). Flavonoid aglycones from Jasonia Montana. J. Phytochemistry, 28: 665-667.

AL-Howiriny, T. A., A. J. Al-Rehailly, J. R. Polsc, J. R. Porter, J. S. Mossa and B. Ahmed (2005). Three new diterpenes and the biological activity of different extracts of Jasonia Montana. Apr, Nat. Prod. Res, 19: 253-265.

Altar, C. A., M. P. Vawter and S. D. Ginsberg (2009). Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology, 34: 18-54.

Ammar, R. B., W. Bhouri, M. B. Sghaier, J. Boubaker, I. Skandrani, A. Neffati, I. Bouhlel, S. Kilani, A. Mariotte, L. Chekir-Ghedira, M. Di- joux-Franca and K. Ghedira (2009). Antioxidant and free radical-scavenging properties of three flavonoids isolated from the leaves of Rhamnus alaternus L. (Rhamnaceae): A structure-activity relationship study. Food Chemistry, 116: 258-264.

Andallu, B. and N. Varadacharyulu (2003). Antioxidant role of mulberry leaves in treptozotocin- diabetic rats. Clin. Chim. Acta., 338: 3-11.

Andarwulan, N., R. Batari, D. A. Sandrasari, B. Bolling and H. Wijaya (2010). Flavonoid content and antioxidant activity of vegetables from Indonesia. Food Chemistry, 121: 1231-1235.

Anjali, P. and K. M. Manoj (1995). Some comments on diabetes and herbal therapy. Ancient Sci. Life, 15: 27-29.

Armitage, P. and G. Berry (1987). Comparison of several groups. In: statistical method in medical research 2th Ed. Blockwell Significant Publication, Oxford, 186-213.

Baydas, G., R. J. Reiter, A. Yasar, M. Tuzcu, I. Akdemir and V. S. Nedzvetskii (2003). Melatonin reduces glial reactivity in the hippocampus, cortex and cerebellum of streptozotocin-induced diabetic rats. Free Radic. Biol. Med.; 35: 797-804.

Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes, 40: 405-415.

Benito, P. B., M. J. Abad, A. M. Diaz, L. Villaescusa, M. A. Gonzalez and A. M. Silvana (2002). Sesquiter-penes from Jasonia glutinosa: In Vitro Anti-inflammatory Activity. Biol. Pharm. Bull., 25: 1-4.

Berchtold, N. C., D. H. Cribbs, P. D. Coleman, J. Rogers, E. Head, R. Kim, T. Beach, C. Miller, J. Tron- coso, J. Q. Trojanowski, H. R. Zielke, C. W. Cotman (2008). Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc. Natl. Acad. Sci. USA, 105: 15605-15610.

Berkels, R., S. Purol-Schnabel and R. Roesen (2004). Measurment of nitric oxide by reconversion of nitrate/nitrite to NO. J. Humman Press., 279: 1-8.

Bio-Rad Laboratories, Inc. (2006). Real-Time PCR Applications Guide. Bulletin 5279, 101.

Bjertness, E., J. M. Candy, A. Torvik, P. Ince, F. Mc-Arthur, G. A. Taylor, S. W. Johansen, J. Alexander, J. K. Grønnesby, L. S. Bakketeig, and J. A. Edwardson (1996). Content of brain aluminum is not elevated in Alzheimer’s disease. Alzheimer's Dis. Assoc. Disord., 10: 171-174.

Bondy, S. C., S. X. Guo-Ross and A. T. Truong (1998). Promotion of transition metal-induced reactive oxygen species formation by beta- amyloid. Brain Res., 799: 91-96.

Breder, C. D., D. DeWitt and R. P. Kraig (1995). Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol., 355: 296-315.

Bustin, S. A. (2000). Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. En- docrinol., 25: 169-193.

Canales, J. J., R. Corbalan, C. Montoliu, M. Liansola, P. Monfort, S. Erceg, V. Hernamdez and V. Felipo (2001). Aluminum impairs the glutamate-nitric oxide cGMP pathway in cultured neurons and in rat brain in vivo L molecular mechanisms and implications for neuropathology. J. Inorg Biochem., 87: 63-69.

Carageorgious, H., A. C. Sideris and E. Messaril (2008). The effect of revastigmine and selegilin on brain acetylcholinesterase, (Na+, K+), Mg2+, Atpase activities, antioxi- dant status and learning performance of aged rats. Neuropsychiatric Disease and Treatment, 4: 687-699.

Cerqueira, F., H. Cidade, L. van Ufford, C. Beukelman, A. Kijjoa and M. S. J. Nascimento (2008). The natural prenylated flavone artelastin is an inhibitor of ROS and NO production. International Immunopharma-cology, 8: 597-602.

Dasgupta, N. and B. De (2007). Antioxidant activity of some leafy vegetables of India: A comparative study. Food Chemistry, 101: 471-474.

Desai, A. and G. Grossberg (2001). Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Expert Opin. Pharmacother, 2: 653-666.

Dorheim, M. A., W. R. Tracey, J. S. Pollock and P. Grammas (1994). Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease. Biochem. Bio-phys. Res. Commun., 205: 659-665.

Erazi, H., W. Sansar, S. Ahboucha and H. Gamrani (2010). Aluminum affects glial system and behavior of rats. C. R. Biol., 333: 23-27.

Esmaeili, M. A., A. Sonboli and M. A. Noushabadi (2010). Antioxidant and protective properties of six Tanacetum species against hydrogen peroxide-induced oxidative stress in K562 cell line: A comparative study. Food Chemistry, 121: 148-155.

Exley, C. (2005). The aluminum amyloid cascade hypothesis and Alzheimer’s disease. Subcell. Biochem., 38: 225-234.

Foye, W. O., T. L. Lemke and D. A. Wil- liams (1995). Principles of Medicinal Chemistry, fourth ed. Williams and Wilkins, USA.

Guix, F. X., I. Uribesalgo, M. Coma and F. J. Munoz (2005). The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol., 76: 126-152.

Hammerschmidt, F. J., A. M. Clark, F. M. Soliman, E. S. A. El-Kashoury and M. M. Abd El-Kawy and A. M. El-Fishawy (1993). Chemical composition and antimicrobial activity of essential oils of Jasonia candicans and Jasonia Montana. Planta Medica, 59: 68-70.

Hardy, J. and D. J. Selkoe (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 297: 353-356.

Howes, M. R., N. S. L. Perry and P. J. Houghton (2003). Plants with traditional uses and activities, relevant to the management of Alzheimer’s disease and other cognitive disor- ders. Phytotherapy Research, 17: 1-18.

Hussein, M. A. (2008). Antidiabetic and antioxidant activity of Jasonia montana extract in Streptozotocin-induced diabetic rats. Saudi Pharmaceutical J., 16: 214-221.

Hussein, M. A. and S. M. Abdel-Gawad (2010). Protective effect of Jasonia montana against ethinylestradiol-induced cholestasis in rats. Saudi Pharmaceutical J., 18: 27-33.

Iadecola, C., C. Forster, S. Nogawa, H. B. Clark and M. E. Ross (1999). Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol., (Berlin) 98: 9-14.

Kaufmann, W. E., K. I. Andreasson, P. C. Isakson and P. F. Worley (1997). Cyclooxygenases and the central nervous system. Prostaglandins,

: 601-624.

Koracevic, D., G. Koracevic, V. Djord- jevic, S. Andrejevic and V. Cosic (2001). Method for the measurement of antioxidant activity in human fluids. J. Clin. Pathol; 54: 356-361.

Kumar, A., S. Dogra and A. Prakash (2009). Protective effect of curcumin (Curcuma longa), against aluminum toxicity: possible behavioral and biochemical alterations in rats. Behav. Brain Res., 205: 384-390.

Kumar, V., A. Bal and K. D. Gill (2008). Impairment of mitochondrial en- ergy metabolism in different regions of rat brain following chronic exposure to aluminum. Brain Res., 1232: 94-103.

Liang, Y. Q. and X. C. Tang (2004). Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci. Lett., 361: 56-59.

Liu, X., C. Cui, M. Zhao, J. Wang, W. Luo, B. Yang and Y. Jiang (2008). Identification of phenolics in the fruit of emblica (Phyllanthus em- blica L.) and their antioxidant activities. Food Chemistry, 109: 909-915.

López, V., S. Akerreta, E. Casanova, J. M. García-Mina, R. Y. Cavero, M. I. Calvo (2008). Screening of Spanish Medicinal Plants for Antioxidant and Antifungal Activities. Pharma- ceutical Biology, 46: 602-609.

Lowry, O. H., N. J. Rosebrough, A. L. Farr and R. J. Randall (1951). Protein measurement with the folin phenol reagent. J. Biol., 193: 265-275.

Lüth, H., M. Holzer, U. Gartner, M. Staufenbiel and T. Arendt (2001). Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res., 913: 57-67.

Luo, Y., B. Bolon, M. D. Damore, D. Fitzpatrick, H. Liu, J. Zhang, Q. Yan, R. Vassar and M. Citron (2003). BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis., 14: 81-88.

Mahieu, S., M. D. Contini, M. Gonzez and N. Millen (2009). Melatonin reduces oxidative damage-induced by aluminum in rat kidney. Toxicol. Lett., 190:9-15.

Mahieu, S., N. Millen, M. Gonzalez, M. Contini, C. Del and M. M. Elias (2005). Alteration of the renal function and oxidative stress in renal tissue from rats chronically- treated with aluminum during the initial phase of hepatic regeneration. J. Inorg. Biochem., 99: 1858-1864.

Merxmuller, H., P. Liens and H. Roesseler (1977). In: J.B. Heywood, J.B. Harborne and B.L. Turner (Eds.). The Biology and Chemistry of Compositae. Academic Press, New York. pp. 590.

Ohkawa, H., N. Ohishi and K. Yagi (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem, 95: 351-358.

Oyama, K., T. Fujimura, I. Ninomiya, T. Miyashita, S. Kinami, S. Fushida, T. Ohta and M. Koichi (2005). A COX-2 inhibitor prevents the esophageal inflammation-metaplasia- adenocarcinoma sequence in rats. Carcinogenesis, 26: 565-570.

Platt, B., D. O. Carpenter, D. Büsselberg, K. G. Reyman and G. Riedel (1995). Aluminum impairs hippocampal long-term potentiation in rats in vitro and in vivo. Exp. Neurol., 134: 73-86.

Robaszkiewicz, A., A. Balcerczyk and G. Bartosz (2007). Antioxidative and prooxidative effects of quercetin on A549 cells. Cell Biol. Int., 31: 1245-1250.

Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. Science, 298: 789-791

Soliman, F. M., M. Y. Moussa, H. M. Abdallah and S. M. Othman (2009). Cytotoxic activity of flavonoids of Jasonia montana vahl. (Botsch). (Astraceae) growing in Egypt. Australian Journal of Basic and Applied Sciences, 3: 148-152.

Stein, T. D. and J. A. Johnson (2002). Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J. Neurosci., 22: 7380-7388.

Sugihara, N., T. Arakawa, M. Ohnishi and K. Furuno (1999). Anti- and pro- oxidative effects of flavonoids on metal-induced lipid hydroperoxide- dependent lipid peroxidation in cultured hepatocytes loaded with α- linolenic acid. Free Radical Biology and Medicine, 27: 1313-1323.

Tackholm, V. (1969). Alfred Kaiser’s Sinai-Herbarium, p. 562. Cairo University Herbium, Cairo.

Tackholm, V. (1974). Students Flora of Egypt, p. 562. Cairo University, Beirut.

Tomimoto, H., I. Akiguchi, H. Wakita, J. X. Lin and H. Budka (2000). Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans. Acta. Neuro-pathol. (Berlin), 99: 26-30.

Vassar, R. and M. Citron (2000). A ß-generating enzymes: recent ad- vances in ß- and γ-secretase research. Neuron, 27: 419-422.

Yasojima, K., C. Schwab, E. G. McGeer and P. L. McGeer (1999). Distribution of cyclooxygenase-1 and cyclooxygenase- 2 mRNAs and proteins in human brain and peripheral organs. Brain Res., 830: 226-236.

Yasojima, K., W. W. Tourtellotte, E. G. McGeer and P. L. McGeer (2001). Marked increase in cyclooxy- genase-2 in ALS spinal cord: implications for therapy. Neurology, 57: 952-956.

Downloads

Published

2016-01-11

Issue

Section

Articles